QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

May 23, 2023

Austin, TX, May 23, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB:QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and other diseases and conditions, today announces the addition of the Insight Research Institute at the Insight Hospital and Medical Center in Chicago, IL, as a clinical trial site approved to begin enrolling participants into the Phase 1 study evaluating CycloSam® in patients with multiple types of bone cancer that either originated in or has metastasized to the bone.

Read more at globenewswire.com

Related news for (QSAM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.